In vitro evolution of the human immunodeficiency virus type 1 Gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure

被引：12

作者：

Catamancio, SL ^{[1
]}

De Pasquale, MP ^{[1
]}

Citterio, P ^{[1
]}

Kurtagic, S ^{[1
]}

Galli, M ^{[1
]}

Rusconi, S ^{[1
]}

机构：

[1] Univ Milan, Osped Luigi Sacco, Inst Malattie Infettive, I-20157 Milan, Italy

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2001年 / 39卷 / 03期

关键词：

D O I：

10.1128/JCM.39.3.1124-1129.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We studied the human immunodeficiency virus type 1 phenotypic and genotypic profiles of a dual drug-resistant isolate (isolate 14aPost-DR) selected for zidovudine (ZDV) and lamivudine (3TC) resistance and then cultured in the presence of 3TC and a protease inhibitor: indinavir (IDV), ritonavir, or KNI-272. The IDV-treated virus was highly resistant to 3TC, ZDV, and IDV and accumulated protease mutations at positions M46I and V82F. A change from alanine to valine was observed in 4 of 10 clones in the P2 position of the p7-p1 Gag-protease cleavage site, linked to position M46I in the dominant viral quasispecies. Previous 3TC resistance did not impair the development of additional mutations in the protease and Gag-protease cleavage regions.

引用

页码：1124 / 1129

页数：6

共 30 条

[1]

[Anonymous], 1995, Phylogeny inference package (PHYLIP)

[2] HIV-1 drug resistance in newly infected individuals [J].

Boden, D ;

Hurley, A ;

Zhang, LQ ;

Cao, YZ ;

Guo, Y ;

Jones, E ;

Tsay, J ;

Ip, J ;

Farthing, C ;

Limoli, K ;

Parkin, N ;

Markowitz, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141

[3] Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug [J].

Borman, AM ;

Paulous, S ;

Clavel, F .

JOURNAL OF GENERAL VIROLOGY, 1996, 77 :419-426

[4] Virological and clinical implications of resistance to HIV-I protease inhibitors [J].

Condra, JH .

DRUG RESISTANCE UPDATES, 1998, 1 (05) :292-299

[5] Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor [J].

Condra, JH ;

Holder, DJ ;

Schleif, WA ;

Blahy, OM ;

Danovich, RM ;

Gabryelski, LJ ;

Graham, DJ ;

Laird, D ;

Quintero, JC ;

Rhodes, A ;

Robbins, HL ;

Roth, E ;

Shivaprakash, M ;

Yang, T ;

Chodakewitz, JA ;

Deutsch, PJ ;

Leavitt, RY ;

Massari, FE ;

Mellors, JW ;

Squires, KE ;

Steigbigel, RT ;

Teppler, H ;

Emini, EA .

JOURNAL OF VIROLOGY, 1996, 70 (12) :8270-8276

[6] IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].

CONDRA, JH ;

SCHLEIF, WA ;

BLAHY, OM ;

GABRYELSKI, LJ ;

GRAHAM, DJ ;

QUINTERO, JC ;

RHODES, A ;

ROBBINS, HL ;

ROTH, E ;

SHIVAPRAKASH, M ;

TITUS, D ;

YANG, T ;

TEPPLER, H ;

SQUIRES, KE ;

DEUTSCH, PJ ;

EMINI, EA .

NATURE, 1995, 374 (6522) :569-571

[7] THE HIV-1 PROTEASE AS A THERAPEUTIC TARGET FOR AIDS [J].

DEBOUCK, C .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) :153-164

[8] HIV-1 protease inhibitors - A review for clinicians [J].

Deeks, SG ;

Smith, M ;

Holodniy, M ;

Kahn, JO .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153

[9] Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors [J].

Doyon, L ;

Croteau, G ;

Thibeault, D ;

Poulin, F ;

Pilote, L ;

Lamarre, D .

JOURNAL OF VIROLOGY, 1996, 70 (06) :3763-3769

[10]

DULBECCO R, 1988, VIROLOGY M, V69, P23

← 1 2 3 →